We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · April 02, 2021

HER2-Positive Result After Neoadjuvant Chemo

Dr. Kawyba , AAA


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bogdan Cristian Dinu

    Apr 03, 2021

    Trastuzumab +\- Pertuzumab without chemo prolonging neoadjuvant therapy for six cycles .Radiotherapy after both supraclavicullar clearance posibile .Endocrine therapy related with imunochemistry notation after tumor resection.

  • Ashraf  Elzayat

    Apr 09, 2021

    I have a very similar case, Er, Pr weak positive, Ger2 +ve. Complete clinical response after ONLY 4 CYCLES AC. starting Taxanes next, I plan surgery before I start Herceptin. If complete pathological response, might omit herceptin!!

  • mohamad kadri

    Apr 09, 2021

    The patient should be considered stage IV (none regional node mets) and treated by anti her2 (Trastuzumab +/_ Pertuzumab) till progression. Local treatment (surgery +/_ RT) may be considered according to the local response.

  • Gabriele Dr.Doering

    Apr 11, 2021

    The same recommandation -like mohamad -also from me !


    Apr 12, 2021

    Her2/neu by FISH, PDL1 and BRCA 1/2, done or not?

  • Dr.kawyba A.A.A

    Apr 12, 2021

    her2 by FISH. What is the role of pdl1 in her2 positive breast cancer. Do you recommend surgery?

  • Rham Zaki

    Oct 09, 2021

    Same as mohamed kadri

  • Jan 27, 2022

    Pending Moderator approval.

Further Reading